Congress pushes 10 drugmakers for heparin info

Unsatisfied with the information it has drawn from the FDA, a congressional committee is broadening its probe into the years-old heparin contamination scandal. The House Energy and Commerce Committee has written 10 drugmakers--including the Novartis generics unit Sandoz, APP Pharmaceuticals and Sanofi--demanding information about the heparin supply chain in China. Release | Letter

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.